0.591 -0.048 (-7.56%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.14 | 1-year : | 1.58 |
Resists | First : | 0.98 | Second : | 1.36 |
Pivot price | 0.79 | |||
Supports | First : | 0.37 | Second : | 0.3 |
MAs | MA(5) : | 0.55 | MA(20) : | 0.88 |
MA(100) : | 1.66 | MA(250) : | 16.47 | |
MACD | MACD : | -0.2 | Signal : | -0.2 |
%K %D | K(14,3) : | 23.9 | D(3) : | 19.9 |
RSI | RSI(14): 35.5 | |||
52-week | High : | 49.79 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SEEL ] has closed above bottom band by 30.8%. Bollinger Bands are 24.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.68 - 0.68 | 0.68 - 0.69 |
Low: | 0.57 - 0.57 | 0.57 - 0.57 |
Close: | 0.59 - 0.59 | 0.59 - 0.6 |
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Tue, 19 Mar 2024
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why - TradingView
Tue, 19 Mar 2024
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS ... - PR Newswire
Tue, 19 Mar 2024
Seelos Therapeutics' ALS treatment fails mid-stage study - Reuters
Mon, 11 Mar 2024
Is Seelos Therapeutics Inc (SEEL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Fri, 08 Mar 2024
Should You Buy Seelos Therapeutics Inc (SEEL) Stock After it Is Down 3.23% in a Week? - InvestorsObserver
Fri, 26 Jan 2024
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced ... - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 14 (M) |
Held by Insiders | 1.34e+007 (%) |
Held by Institutions | 2 (%) |
Shares Short | 409 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 226.8 % |
Return on Equity (ttm) | -179.8 % |
Qtrly Rev. Growth | 2.2e+006 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -7.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -24 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -0.35 |
Dividend | 0 |
Forward Dividend | 292950 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |